[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2016020697A1 - Compositions pharmaceutiques de monoparticules polymères - Google Patents

Compositions pharmaceutiques de monoparticules polymères Download PDF

Info

Publication number
WO2016020697A1
WO2016020697A1 PCT/GB2015/052288 GB2015052288W WO2016020697A1 WO 2016020697 A1 WO2016020697 A1 WO 2016020697A1 GB 2015052288 W GB2015052288 W GB 2015052288W WO 2016020697 A1 WO2016020697 A1 WO 2016020697A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
composition according
nanoparticles
pharmaceutically acceptable
anticancer drugs
Prior art date
Application number
PCT/GB2015/052288
Other languages
English (en)
Inventor
Shruti SHRIKHANDE
Amrita N BAJAJ
Geena Malhotra
Preeti Raut
Original Assignee
Cipla Limited
King, Lawrence
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Limited, King, Lawrence filed Critical Cipla Limited
Publication of WO2016020697A1 publication Critical patent/WO2016020697A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Definitions

  • the present invention relates to pharmaceutical compositions comprising polymeric nanoparticles of anticancer drugs, a process for preparing such pharmaceutical compositions and their use in the treatment of liver cancer, specifically hepatocellular carcinoma.
  • Liver cancer is one of the most widespread forms of cancer and the major reason for tumor related mortality. Globally, more than 6,00,000 cases of death per year are associated with hepatic cancer. Although, liver cancer is observed more commonly in the developing countries, its instances are increasing at an alarming rate throughout the world.
  • Hepatocellular carcinoma comprises of around 95% of the primary liver cancers followed by cholangiocarcinoma (3.4%) and other cancers (1%). Hence, most of the antineoplastic treatments in patients are directed towards hepatocellular carcinoma.
  • hepatocellular carcinoma Current treatments for hepatocellular carcinoma include surgical resection, chemotherapy, liver transplant, chemoembolization, trans -arterial embolization, radiation therapy, ethanol injection and cryoablation.
  • Liver resection is the best suitable treatment for non-cirrhotic liver cancer subjects.
  • the chances of resection and post-operative survival are better in non-cirrhotic patients than those suffering from cirrhosis.
  • this therapy holds limitations like suitability for small tumors.
  • Liver transplantation proves to be a boon for patients with small tumor size ( ⁇ 5 cm), but suffers from restricted amount of donors and delay due to the donor non-availability.
  • Chemotherapy although widely used to treat tumors, results in more side effects and toxicity due to the destruction of normal, non-malignant cells.
  • Drug delivery to the tumors occurs through endothelial junctions, fenestrations and vesicular organelles.
  • Factors like P-glycoprotein mediated drug efflux and changes in enzyme activity add to failure via chemotherapy.
  • Pharmacokinetics is an important parameter to be considered during chemotherapy.
  • cancerous cells should be exposed to suitable concentrations of drug over an extended time period. Current chemotherapy treatments are given over a short period of time with time intervals of 2-3 weeks. This results in speedy growth of tumors and thus diminishes the therapeutic effects of drugs with untoward side effects.
  • hepatocellular carcinoma is performed by use of anthracycline antibiotics like doxorubicin, mitomycin, alkylating agent like cisplatin and other drugs like floxuridine, bevacizumab and sorafenib tosylate.
  • anthracycline antibiotics like doxorubicin, mitomycin, alkylating agent like cisplatin and other drugs like floxuridine, bevacizumab and sorafenib tosylate.
  • Radiofrequency ablation has a curative effect on liver cancer because of lesser sessions required for therapy, but possesses more complications than percutaneous ethanol injection.
  • Therapeutic effects with other treatments prove to be inadequate due to metastasis of tumors, lack of suitable embolizing materials, non-specificity to tumor cells and greater number of complications.
  • liver cancer In spite of various therapies available for hepatocellular carcinoma, none have sufficed in complete and side effect free treatment of hepatic cancer. In this respect, many other alternative treatments have been explored for treatment of liver cancer such as nanoparticles.
  • Nanoparticles are minute, solid particulates in the size range of 10-1000 nm where, an anticancer agent is either entrapped in the core, adsorbed on the surface or both. Nanospheres or nanocapsules could be prepared by varying the methodology for synthesis of these colloidal carriers. The aim of any cancer treatment is to ensure optimum drug delivery to the desired cancerous site. The potential of using nanoparticles for delivery of anticancer drugs is massive and can be applied to various areas of medicine.
  • Nanotechnology in oncology Characterization and in vitro release kinetics of cisplatin-loaded albumin nanoparticles: Implications in anticancer drug delivery, Indian J Pharmacol. 2011 Jul- Aug; 43(4): 409-413. Protein Nanoparticles as Drug Delivery Carriers for Cancer Therapy, BioMed Research International, Warangkana Lohcharoenkal et al, Volume 2014 (2014).
  • An object of the present invention is to provide a pharmaceutical composition comprising polymeric nanoparticles of anticancer drugs.
  • Another object of the present invention is to provide a pharmaceutical composition comprising polymeric nanoparticles of anticancer drugs optionally with one or more pharmaceutically acceptable excipients.
  • Another object of the present invention is to provide a pharmaceutical composition comprising polymeric nanoparticles of anticancer drugs exhibiting prolonged release thereby leading to reduced frequency of dosing.
  • Another object of the present invention is to provide a pharmaceutical composition comprising polymeric nanoparticles of anticancer drugs having improved surface area and solubility.
  • Another object of the present invention is to provide a pharmaceutical composition comprising polymeric nanoparticles of anticancer drugs having a reduced dose.
  • Another object of the present invention is to provide a pharmaceutical composition comprising polymeric nanoparticles of anticancer drugs with minimized irritation potential at the site of action thus leading to increased patient compliance.
  • Another object of the present invention is to provide a pharmaceutical composition comprising polymeric nanoparticles of anticancer drugs to deliver the said anticancer drugs to the target site of action as well as attempt to decrease or avoid the side effects.
  • Another object of the present invention is to provide a process for preparing a pharmaceutical composition comprising homogenous polymeric nanoparticles of anticancer drugs optionally with one or more pharmaceutically acceptable excipients.
  • Another object of the present invention is to provide the use in the treatment of hepatocellular carcinoma by administering a pharmaceutical composition comprising polymeric nanoparticles of anticancer drugs.
  • Another object of the present invention is to provide the use of a pharmaceutical composition comprising polymeric nanoparticles of anticancer drugs and optionally one or more pharmaceutically acceptable excipients in the manufacture of a medicament for treatment of hepatocellular carcinoma.
  • Another object of the present invention is to provide a method of treating hepatocellular carcinoma by administering a pharmaceutical composition comprising polymeric nanoparticles of anticancer drugs.
  • a pharmaceutical composition comprising polymeric nanoparticles of one or more anticancer drugs, and optionally one or more pharmaceutically acceptable excipients.
  • composition comprising polymeric nanoparticles of one or more anticancer drugs, and optionally, one or more pharmaceutically acceptable excipients, wherein the composition is formulated to deliver said anticancer drugs to the target site of action as well as attempt to decrease or avoid the side effects.
  • a process for the preparation of a pharmaceutical composition comprising polymeric nanoparticles of one or more anticancer drugs, wherein the process comprises formulating the polymeric nanoparticles with one or more pharmaceutically acceptable excipients.
  • the process comprises dissolving the one or more anticancer drugs in aqueous solution of human serum albumin or gelatin; adding a desolvating agent for formation of nanoprecipitates; cross linking and neutralization of the formed nanoparticles with other pharmaceutically acceptable excipients; optionally freeze drying the purified nanoparticles; and processing into a dosage form.
  • a pharmaceutical composition comprising polymeric nanoparticles of one or more anticancer drugs and optionally one or more pharmaceutically acceptable excipients for use in the treatment of hepatocellular carcinoma.
  • a pharmaceutical composition comprising polymeric nanoparticles of one or more anticancer drugs and optionally one or more pharmaceutically acceptable excipients in the manufacture of a formulation for treating hepatocellular carcinoma.
  • a method of treating hepatocellular carcinoma comprising administering a pharmaceutical composition comprising polymeric nanoparticles of one or more anticancer drugs and optionally one or more pharmaceutically acceptable excipients. to a patient in need thereof.
  • Plain cisplatin exhibited quick dissolution in phosphate buffer saline (pH 7.4) within 4 hours due to its short half-life after intravenous administration.
  • HSA-TG nanoparticle formulation exhibited a sustained release pattern for 72 hours. In case of gelatin nanoparticles, sustained release profile for more than 72 hours was observed. Around 70% of the drug was released in 8 hours followed by a controlled release pattern beyond this point.
  • the concentration of cisplatin gelatin nanoparticles in the liver increased slowly untill 48 hours; however, this concentration was found to reduce over 96 hours. Concurrently, plain cisplatin concentration was found to rise steadily in the lungs over a period of 96 hours.
  • the initial high concentration of cisplatin gelatin nanoparticles in the liver was attributed to the enhanced permeability and retention (EPR) effect leading to rapid distribution in the liver followed by subsequent distribution in lungs.
  • EPR enhanced permeability and retention
  • Some amount of cisplatin gelatin nanoparticles after i.v. administration could reach the kidney and brain tissues over a period of 24 hours. However, over a time period of 96 hours, the concentration in the brain was found to reduce and increased in liver and lungs.
  • FIG. 4 & Figure 5 Biodistribution studies on passively targeted and actively targeted cisplatin albumin nanoparticles
  • concentration of cisplatin in case of non-targeted cisplatin albumin nanoparticles was maximum in case of liver and was seen to be 4 - 6 times higher as compared to other highly perfused organs. This phenomenon may be related to the preferential uptake of negatively charged albumin nanoparticles by the liver due to enhanced permeability and retention (EPR) effect.
  • EPR enhanced permeability and retention
  • the concentration of cisplatin was highest at 48 hours and was maintained throughout the time period of 96 hours in this study, due to slow diffusion of cisplatin from the albumin matrix.
  • the main aim of anticancer therapy is to ensure specific drug action at the target site/tissue/organ along with reduced distribution to other non-specific organs.
  • Target oriented drug delivery systems can provide maximum therapeutic benefit through controlled and predetermined release rate kinetics, prevent drug degradation or inactivation during transit to target sites and prevent the body from adverse reactions. For drugs that possess low therapeutic index, these systems can provide effective treatment at low concentrations.
  • Nanoparticles due to their colloidal nature, offer numerous advantages over conventional treatment strategies. Small sized particles possess large surface area and hence increase the dissolution properties of antineoplastic agents with poor solubility. Nanoparticles can be tailored to reach specific tumor sites by modulation of their size, surface characteristics, and particle charge.
  • anticancer agents in the form of nanoparticles also ensures reduction in their therapeutic dosage and frequency of administration due to the controlled release properties of the nanosy stems.
  • nanoparticulate drug delivery systems reduce the untoward toxicities associated with antitumor agents and prevent their degradation.
  • Site specific targeting is possible with nanoparticles after attachment of certain ligands, antibodies or carriers on the surface by physical adsorption or covalent attachment.
  • Nanoparticles possess the ability to increase the absorption of anticancer agents from the body upon administration, thus causing a concomitant rise in their bioavailability.
  • Nanoparticles are biocompatible and non-immunogenic and can entrap hydrophilic and hydrophobic moieties, proteins, vaccines and biological macromolecules.
  • nanoparticles can be prepared using both nonbiodegradable and biodegradable polymers. However, the later are preferred due to their biocompatibility, biodegradability, low cost and safety. These particles can be delivered by various routes of administration like nasal, oral, dermal and ocular, apart from parenteral route. Biodegradable polymeric nanocarriers are favorable due to their excellent biocompatibility, biodegradability and low toxic potential.
  • Preferred biodegradable polymers include, but are not limited to, natural polymers like gelatin, human serum albumin, sodium alginate, agarose, casein, zein, chitosan, glycol chitosan, N, N trimethyl chitosan, starch, cellulose and wheat gluten, or combinations thereof.
  • HSA Human Serum Albumin
  • HSA Human Serum Albumin
  • HSA is the most important soluble protein in human body, which is synthesized in the liver. It is the primary protein in human body controlling the osmotic pressure of serum.
  • Other functions imparted by albumin include binding of toxic products and their transport to the liver, distribution and transport of metal ions and other exogenous components.
  • Albumin is an acidic protein with an isoelectric point of 4.7. This protein is stable in the pH range of 4-9 and exhibits solubility in water and other aqueous solutions. Albumin can be heated at a temperature of around 60°C, without any change in the protein structure. All these properties along with the preferential tumor uptake, biodegradability, non-toxicity and property to accumulate at inflamed tissues, makes it an ideal polymer for cancer drug delivery.
  • gelatin a natural macromolecule is commonly employed as a pharmaceutical adjuvant and an encapsulating drug material.
  • Advantages of gelatin for drug delivery include its inexpensiveness, ability to be sterilized, free from contamination with pyrogens and low antigenicity.
  • the polymers may be present in the pharmaceutical composition of the present invention an amount ranging from about 0.1% to about 35% by weight of the composition.
  • human serum albumin and gelatin, or combinations thereof are the preferable polymers that have been employed in the pharmaceutical composition comprising polymeric nanoparticles of anticancer drugs.
  • the pharmaceutical composition according to the present invention, comprises polymeric nanoparticles of one or more anticancer drugs.
  • the pharmaceutical composition comprising polymeric nanoparticles of one or more anticancer drugs have been engineered to have an affinity for target tissues through passive or active targeting mechanisms.
  • the pharmaceutical composition comprising polymeric nanoparticles of one or more anticancer drugs deliver the said anticancer drugs to the target site of action as well as attempt to decrease or avoid the side effects.
  • the pharmaceutical composition comprising polymeric nanoparticles of one or more anticancer drugs exhibits prolonged release.
  • the pharmaceutical composition comprising polymeric nanoparticles of one or more anticancer drugs which have a reduced dose.
  • Anticancer drugs according to the present invention include, but are not limited to alkylating agents, antitumor antibiotics, anti-microtubule agents, DNA linking agents, bisphosphonates, topoisomerase inhibitors, antimetabolites, biological agents and nucleoside analogues, or any combinations thereof.
  • Suitable alkylating agents include, but are not limited to, mechlorethamine, mustine, cyclophosphamide, nitrosoureas, tetrazine, azidine, melphalan, chlorambucil, busulfan, uramustine, bendamustine, ifosfamide, lomustine, semustine, carmustine, fotemustine, streptozotocin, thiotepa, dacarbazine, procarbazine, mitomycin, mitozolomide, temozolomide and the like or combinations thereof.
  • Suitable DNA linking agents include, but are not limited to, cisplatin, carboplatin, nedaplatin, oxaliplatin, satraplatin and the like or combinations thereof
  • Suitable antitumor antibiotics and topoisomerase inhibitors include, but are not limited to, bleomycin, daunorubicin, epirubicin, doxorubicin, idarubicin, mitoxantrone, mitomycin, actinomycin, pirarubicin and the like or combinations thereof.
  • Suitable antimetabolites according to the present invention include, but are not limited to, fluorouracil, capecitabine, asparaginase, cladribine, nelarabine, decitabine, clofarabine, pentostatin, methotrexate, pemetrexed, raltitrexed, asparaginase, thioguanine, mercaptopurine and the like or combinations thereof.
  • Suitable biological agents include, but are not limited to, bevacizumab, cetuximab, regorafenib, ibrutinib, axitinib, crizotinib, dabrafenib, ponatinib, afatinib, dasatinib, nilotinib ruxolitinib, trametinib, erlotinib, sorafenib, gefitinib, imatinib, interferon, lapatinib, ipilimumab, denosumab, panitumumab, rituximab, sunitinib, emsirolimus, trastuzumab and the like or combinations thereof.
  • Suitable nucleoside analogues include, but are not limited to, didanosine, vidarabine, abacavir, acyclovir, entecavir, cytarabine, lamivudine, emtricitabine, stavudine, telbivudine, idoxuridine, trifluridine, zidovudine and the like or combinations thereof.
  • anticancer agents include, but are not limited to, mesna, octreotide, tamoxifen, anastrozole, amifostine, bexarotene, bicalutamide, buserelin, exemestane, flutamide, folinic acid, cyproterone, degarelix, folinic acid, fulvestrant, goserelin, lanreotide, letrozole, medroxyprogesterone, megestrol, stilbestrol, thalidomide and the like or combinations thereof.
  • the pharmaceutical composition according to the present invention may comprise human serum albumin nanoparticles as well as gelatin nanoparticles of cisplatin.
  • cisplatin is used in a broad sense to include not only “cisplatin” per se but also its pharmaceutically acceptable derivatives thereof. Suitable derivatives include pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, pharmaceutically acceptable isomers, pharmaceutically acceptable esters, pharmaceutically acceptable anhydrates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable polymorphs, pharmaceutically acceptable prodrugs, pharmaceutically acceptable tautomers and/or pharmaceutically acceptable complexes thereof.
  • the pharmaceutical composition comprises polymeric nanoparticles of one or more anticancer drugs which can be administered by varying routes of administration such as, but not limited to oral, parenteral (subcutaneous, intravenous, intramuscular, intradermal, intraperitoneal) or topical or localized (directly at the site)and the like.
  • routes of administration such as, but not limited to oral, parenteral (subcutaneous, intravenous, intramuscular, intradermal, intraperitoneal) or topical or localized (directly at the site)and the like.
  • the pharmaceutical composition comprises albumin as well as gelatin nanoparticles of one or more anticancer drugs, which can be provided as but not limited to oral, parenteral or topical dosage forms, localized and the like.
  • composition includes oral dosage forms, such as but not limited to, tablets, soft gelatin capsule, capsules (filled with powders, powders for reconstitution, pellets, beads, mini-tablets, pills, micro-pellets, small tablet units, MUPS, disintegrating tablets, dispersible tablets, granules, sprinkles, microspheres and multiparticulates), sachets (filled with powders, pellets, beads, mini-tablets, pills, micro-pellets, small tablet units, MUPS, disintegrating tablets, dispersible tablets, granules, sprinkles microspheres and multiparticulates) and sprinkles, however, other dosage forms such as liquid dosage forms (liquids, liquid dispersions, suspensions, solutions, emulsions, sprays, spot-on), micro-formulations, nanoformulations may also be envisaged under the ambit of the invention.
  • oral dosage forms such as but not limited to, tablets, soft gelatin capsule, capsules (filled with powders, powders for reconstitution, pellets, beads, mini-
  • pharmaceutical composition includes parenteral dosage forms such as liquid dosage forms (liquids, liquid dispersions, suspensions, solutions, emulsions, powders for reconstitution), gels, bolus, depots, implants (rods, capsules, rings) biodegradable or nonbiodegradable microparticles/microspheres etc. may also be envisaged under the ambit of the invention.
  • pharmaceutical composition includes topical dosage forms, such as but not limited to, sprays, solutions, suspensions, ointments, drops, in-situ gel, aerosols, ointments, microspheres, creams, gels, patches, films and the like.
  • the pharmaceutical composition of the present invention may comprise polymeric nanoparticles of one or more anticancer drugs, in the form of controlled release formulations, lyophilized formulations, delayed release formulations, timed release formulations, extended release formulations, pulsatile release formulations, and mixed immediate release and controlled release formulations.
  • the pharmaceutical compositions of the present invention comprising polymeric nanoparticles of one or more anticancer drugs are provided in parenteral dosage forms.
  • composition of the present invention comprising polymeric nanoparticles of one or more anticancer drugs can be provided in a lyophilized parenteral dosage form, these dosage forms are to be dissolved or reconstituted in a suitable solvent prior to administration.
  • Suitable solvents for reconstitution include but are not limited to purified water for injection, sterile saline solution, dextrose solution, Ringer's solution and the like.
  • the present invention thus provides a pharmaceutical composition
  • a pharmaceutical composition comprising polymeric nanoparticles of one or more anticancer drugs, wherein the nanoparticles have an average particle size of less than or equal to about 2000 nm, preferably less than or equal to about 1000 nm.
  • average particle size refers to the average diameter of the particles.
  • particles refers to an individual particle of the polymeric nanoparticle comprising anticancer drug(s), or the polymeric nanoparticles comprising anticancer drug(s).
  • Suitable processes for preparing polymeric nanoparticles in accordance with the present invention include, but not limited to, milling, precipitation, homogenization, high pressure homogenization, spray-freeze drying, supercritical fluid technology, double emulsion/solvent evaporation, desolvation, PRINT (Particle replication in non-wetting templates), thermal condensation, ultrasonication, interfacial polymerisation, spray drying and combinations thereof
  • the polymeric nanoparticles of the present invention are prepared by the process of desolvation.
  • the process of desolvation can comprise dissolving the anticancer drug in aqueous solution of one or more polymers, such as human serum albumin or gelatin, and adding a desolvating agent for formation of nanoprecipitates, which are further cross linked and then neutralized. Further, the purified nanoparticles are optionally freeze dried.
  • Suitable desolvating agents according to the present invention include, but are not limited to, acetone, ethanol or isopropanol and the like or combinations thereof.
  • Suitable cross linkers for the stabilization of polymers such as human serum albumin or gelatin nanoparticles according to the present invention include, but are not limited to, bifunctional aldehydes like glutaraldehyde and formaldehyde, carbodiimides (EDC), enzymes such as transglutaminase or thermal processes and the like or combinations thereof.
  • EDC carbodiimides
  • one or more cross linkers may be present in an amount ranging from about 0.1% to about 20% by weight of the total composition.
  • Suitable neutralizers according to the present invention include, but are not limited to, glycine, lysine, sodium metabisulphite, sodium sulphate and the like or combinations thereof.
  • one or more neutralizers may be present in an amount ranging from about 0.1% to about 20% by weight of the total composition.
  • Suitable cryoprotectants according to the present invention include,but are not limited to, sucrose, trehalose, dextrose, mannose, glycine, glucose, galactose, lactose and the like or combinations thereof.
  • one or more cryoprotectants may be present in an amount ranging from about 0.1 % to about 20% by weight of the total composition.
  • Suitable pH adjusting agents or buffering agents that may be used in the pharmaceutical composition include, but are not limited to, hydrochloric acid, acetic acid, citric acid, tartaric acid, propionic acid, sodium hydroxide, sodium phosphate, ammonia solution, triethanolamine, sodium borate, sodium carbonate, sodium acetate, potassium hydroxide and the like or combinations thereof.
  • one or more buffering agent may be present in an amount ranging from about 0.1% to about 10% by weight of the total composition.
  • Suitable solvents/co-solvents, solubilizer or vehicles, that may be employed, in the pharmaceutical composition include, but are not limited to, dichloromethane, acetonitrile, ethyl acetate, acetone, propylene carbonate, water, glycerine, coconut fatty acid diethanolamide, medium and/or long chain fatty acids or glycerides, monoglycerides, diglycerides, triglycerides, structured triglycerides, soyabean oil, peanut oil, corn oil, corn oil mono glycerides, corn oil di glycerides, corn oil triglycerides, polyethylene glycol, caprylocaproylmacroglycerides, caproyl 90, propylene glycol, polyoxyethylenesorbitan fatty acid esters, polyoxyethylene castor oil derivatives, castor oil, cottonseed oil, olive oil, safflower oil, peppermint oil, coconut oil, palm seed oil, beeswax, o
  • the present invention also provides the use of a pharmaceutical composition comprising polymeric nanoparticles of one or more anticancer drugs for the treatment of hepatocellular carcinoma.
  • the said pharmaceutical composition may further comprise one or more active in particular other anticancer drugs, such as, but are not limited to, alkylating agents, antimetabolites, anti-microtubule agents, topoisomerase inhibitors or antitumor antibiotics, DNA linking agents, biological agents and bisphosphonates.
  • active in particular other anticancer drugs such as, but are not limited to, alkylating agents, antimetabolites, anti-microtubule agents, topoisomerase inhibitors or antitumor antibiotics, DNA linking agents, biological agents and bisphosphonates.
  • Cisplatin was added to the aqueous human serum albumin solution while stirring after pH adjustment. .
  • step (2) The nanoparticles obtained in step (2) were cross linked with glutaraldehyde under stirring.
  • the nanoparticle solution obtained in step (4) was ultracentrifuged, redispersed in phosphate buffered saline (PBS), lyophilized and provided with a sterile solution for reconstitution.
  • PBS phosphate buffered saline
  • Cisplatin was added to the aqueous human serum albumin solution while stirring after pH adjustment.
  • step (2) The nanoparticles obtained in step (2) were cross linked with glutaraldehyde under stirring.
  • the nanoparticle solution obtained in step (4) was ultracentrifuged, redispersed in chilled phosphate buffered saline (PBS) containing galactosamine and EDC, lyophilized and provided with a sterile solution for reconstitution.
  • PBS phosphate buffered saline
  • Cisplatin was added to aqueous human serum albumin solution under stirring after adjustment. 2. Ethanol was added to the solution obtained in step (1) to cause precipitation of the protein molecules leading to the formation of nanoparticles.
  • step (2) The nanoparticles obtained in step (2)were cross linked with transglutaminase enzyme under stirring
  • step (4) The nanoparticle solution obtained in step (4) was ultracentrifuged, redispersed in phosphate buffered saline (PBS), lyophilized and provided with a sterile solution for reconstitution.
  • PBS phosphate buffered saline
  • Gelatin was dissolved in water and acetone was added.
  • LMW low molecular weight
  • step (3) The pH of gelatin solution obtained in step (2) was adjusted and cisplatin was dissolved in it and gelatin was desolvated again by addition of acetone leading to the formation of nanoparticles.
  • the nanoparticle solution obtained in step (5) was ultracentrifuged, redispersed in phosphate buffered saline (PBS), lyophilized and provided with a sterile solution for reconstitution.
  • PBS phosphate buffered saline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques comprenant des nanoparticules polymères de médicaments anticancéreux.
PCT/GB2015/052288 2014-08-06 2015-08-06 Compositions pharmaceutiques de monoparticules polymères WO2016020697A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2529MU2014 2014-08-06
IN2529/MUM/2014 2014-08-06

Publications (1)

Publication Number Publication Date
WO2016020697A1 true WO2016020697A1 (fr) 2016-02-11

Family

ID=53836617

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2015/052288 WO2016020697A1 (fr) 2014-08-06 2015-08-06 Compositions pharmaceutiques de monoparticules polymères

Country Status (1)

Country Link
WO (1) WO2016020697A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9655857B2 (en) 2015-03-03 2017-05-23 Pharmacyclics Llc Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
US9713617B2 (en) 2012-06-04 2017-07-25 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
US20180028537A1 (en) 2014-08-07 2018-02-01 Pharmacyclics Llc Novel Formulations of a Bruton's Tyrosine Kinase Inhibitor
WO2018033941A3 (fr) * 2016-08-19 2018-04-05 Cipla Limited Compositions pharmaceutiques à base d'ibrutinib
US10940149B1 (en) 2018-06-15 2021-03-09 Handa Oncology, Llc Kinase inhibitor salts and compositions thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033486A1 (fr) * 1997-01-30 1998-08-06 Quadrant Healthcare (Uk) Limited Procede et appareil pour le traitement de dechets hospitaliers
US20090181090A1 (en) * 2005-12-27 2009-07-16 Sebastian Dreis Protein-Based Carrier System for Overcoming Resistance in Tumour Cells
WO2014059022A1 (fr) * 2012-10-09 2014-04-17 The Brigham And Women's Hospital, Inc. Nanoparticules pour l'administration ciblée d'agents thérapeutiques multiples et procédés d'utilisation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033486A1 (fr) * 1997-01-30 1998-08-06 Quadrant Healthcare (Uk) Limited Procede et appareil pour le traitement de dechets hospitaliers
US20090181090A1 (en) * 2005-12-27 2009-07-16 Sebastian Dreis Protein-Based Carrier System for Overcoming Resistance in Tumour Cells
WO2014059022A1 (fr) * 2012-10-09 2014-04-17 The Brigham And Women's Hospital, Inc. Nanoparticules pour l'administration ciblée d'agents thérapeutiques multiples et procédés d'utilisation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHOJIRO KYOTANI ET AL: "A STUDY OF EMBOLIZING MATERIALS FOR CHEMO-EMBOLIZATION THERAPY OF HEPATOCELLULAR CARCINOMA: ANTITUMOR EFFECT OF CIS-DIAMMINEDICHLOROPLATINUM(II) ALBUMIN MICROSPHERES, CONTAINING CHITIN AND TREATED WITH CHITOSAN ON RABBITS WITH VX2 HEPATIC TUMORS", CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN, JP, vol. 40, no. 10, 1 October 1992 (1992-10-01), pages 2814 - 2816, XP000324875, ISSN: 0009-2363 *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10294232B2 (en) 2012-06-04 2019-05-21 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
US9713617B2 (en) 2012-06-04 2017-07-25 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
US9725455B1 (en) 2012-06-04 2017-08-08 Pharmacyclics Llc Crystalline forms of a bruton's tyrosine kinase inhibitor
US9828383B1 (en) 2012-06-04 2017-11-28 Pharmacyclic s LLC Crystalline forms of a bruton's tyrosine kinase inhibitor
US10961251B1 (en) 2012-06-04 2021-03-30 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
US10752634B2 (en) 2012-06-04 2020-08-25 Pharmacyclics Llc Crystalline forms of a brutons tyrosine kinase inhibitor
US10065968B2 (en) 2012-06-04 2018-09-04 Pharmacyclics Llc Crystalline forms of a bruton's tyrosine kinase inhibitor
US10106548B2 (en) 2012-06-04 2018-10-23 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
US10125140B1 (en) 2012-06-04 2018-11-13 Pharmacyclics Llc Crystalline forms of a bruton's tyrosine kinase inhibitor
US10294231B2 (en) 2012-06-04 2019-05-21 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
US10266540B2 (en) 2012-06-04 2019-04-23 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
US20180028537A1 (en) 2014-08-07 2018-02-01 Pharmacyclics Llc Novel Formulations of a Bruton's Tyrosine Kinase Inhibitor
US10828259B2 (en) 2015-03-03 2020-11-10 Pharmacyclics Llc Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
US10213386B2 (en) 2015-03-03 2019-02-26 Pharmacyclics Llc Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
US10010507B1 (en) 2015-03-03 2018-07-03 Pharmacyclics Llc Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor
US9655857B2 (en) 2015-03-03 2017-05-23 Pharmacyclics Llc Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
WO2018033941A3 (fr) * 2016-08-19 2018-04-05 Cipla Limited Compositions pharmaceutiques à base d'ibrutinib
US10940149B1 (en) 2018-06-15 2021-03-09 Handa Oncology, Llc Kinase inhibitor salts and compositions thereof
US11007195B2 (en) 2018-06-15 2021-05-18 Handa Oncology, Llc Kinase inhibitor salts, and compositions thereof
US11052088B2 (en) 2018-06-15 2021-07-06 Handa Oncology, Llc Kinase inhibitor salts, and compositions thereof
US11160805B2 (en) 2018-06-15 2021-11-02 Handa Onocology, Llc Kinase inhibitor salts and compositions thereof
US12064428B2 (en) 2018-06-15 2024-08-20 Handa Oncology, Llc Kinase inhibitor salts and compositions thereof
US12064430B2 (en) 2018-06-15 2024-08-20 Handa Oncology, Llc Kinase inhibitor salts and compositions thereof

Similar Documents

Publication Publication Date Title
Abourehab et al. Cubosomes as an emerging platform for drug delivery: A review of the state of the art
Saikia et al. Chitosan: A promising biopolymer in drug delivery applications
Kamel et al. Inhalable dual-targeted hybrid lipid nanocore–protein shell composites for combined delivery of genistein and all-trans retinoic acid to lung cancer cells
US11471422B2 (en) Stealth, targeted nanoparticles (STN) for oral drug delivery
JP6580799B2 (ja) 標的疎水性抗腫瘍薬物ナノ製剤及びその調製方法
ES2385995B2 (es) Nanocápsulas con cubierta polimérica
WO2016020697A1 (fr) Compositions pharmaceutiques de monoparticules polymères
Bandawane et al. A review on novel drug delivery system: a recent trend
KR20110056042A (ko) 종양세포 표적지향을 위한 나노 입자 및 이의 제조방법
WO2014155146A1 (fr) Nanocomposition stable comprenant du paclitaxel, procédé pour sa préparation, son utilisation et compositions pharmaceutiques la contenant
JP2020515638A (ja) 経血液脳関門的、経粘膜的及び経皮的薬物送達のための変形可能なナノスケールビヒクル（ｄｎｖ）
Wang et al. Lipoyl ester terminated star PLGA as a simple and smart material for controlled drug delivery application
WO2015087083A1 (fr) Compositions pharmaceutiques intranasales a base de nanoparticules polymères
CN104622817A (zh) 一种蛋白-聚合物复合纳米载体及其制备方法
Tariq et al. Nanogel-Based transdermal drug delivery system: A therapeutic strategy with under discussed potential
Shahzad et al. Bioactive albumin-based carriers for tumour chemotherapy
WO2009116556A1 (fr) Composition pharmaceutique pour injection
Binaymotlagh et al. Liposome–Hydrogel Composites for Controlled Drug Delivery Applications
Liang et al. Development of tetracycline-modified nanoparticles for bone-targeted delivery of anti-tubercular drug
Chandra et al. An overview: The novel carrier for vesicular drug delivery system
US11096893B2 (en) Glucose sensitive compositions for drug delivery
Krasnopol’skii et al. Prospective clinical applications of nanosized drugs
Paul V et al. Self-Assembled Nanobiomaterials for Combination Immunotherapy
Mongia et al. Multifunctional nanocarrier-mediated delivery for targeting and treating skin cancer
Xie et al. A novel therapeutic outlook: Classification, applications and challenges of inhalable micron/nanoparticle drug delivery systems in lung cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15750450

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15750450

Country of ref document: EP

Kind code of ref document: A1